

10/585640

APS Rec'd PCT/PTO 07 JUL 2006

Docket No. 3443-4006
CUSTOMER NO. 27123

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants: **Masao SHIOZAKI and Takaichi SHIMOZATO**
Group Art Unit: **TBA**
Serial No.: **TBA**
Examiner: **TBA**
Filed: **HEREWITH (July 7, 2006)**
For: **LEFT-SIDE GLUCOSE LIPID A ANALOGUE**

INFORMATION DISCLOSURE STATEMENT

Mail Stop PCT
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

This Information Disclosure Statement is filed in accordance with 37 C.F.R. §§1.56, 1.97 and 1.98. The items listed on Form PTO-1449, a copy of which is enclosed, are made of record to assist the Patent and Trademark Office in its examination of this application. The Examiner is respectfully requested to fully consider the items and to independently ascertain their teaching.

1. For each of the following items listed on the enclosed copy of Form PTO-1449 that is not in the English language, an English language translation of that item or a portion thereof or a concise explanation of the relevance of that item is enclosed:

2. For each of the following items listed on the enclosed copy of Form PTO-1449 that is not in the English language, a concise explanation of the relevance of that item is incorporated in the specification of the above-identified application.

3. Any copy of the items listed on the enclosed copy of Form PTO-1449 that is not enclosed with this Information Disclosure Statement was previously cited by or submitted to the Patent and Trademark Office in application Serial No. _____, filed _____.

10/585640 DCT/PTO 07 JUL 2006

4. No fee is due under 37 C.F.R. §1.17(p) for this Information Disclosure Statement since it is being filed in compliance with:

37 C.F.R. §1.97(b)(1), within three months of the filing date of a national application other than a CPA; or

37 C.F.R. §1.97(b)(2), within three months of the date of entry into the national stage as set forth in §1.491 in an international application; or

37 C.F.R. §1.97(b)(3), before the mailing date of a first Office action on the merits; or

37 C.F.R. §1.97(b)(4), before the mailing date of a first office action after the filing of an RCE under §1.114.

The Commissioner is hereby authorized to charge any additional fees which may be required for this Information Disclosure Statement, or credit any overpayment to Deposit Account No. 13-4500, Order No. 3443-4006.

Respectfully submitted,
MORGAN & FINNEGAN, L.L.P.

Dated: July 7, 2006

By: 

Kenneth H. Sonnenfeld
Reg. No. 33,285

Correspondence Address:

MORGAN & FINNEGAN, L.L.P.
3 World Financial Center
New York, NY 10281-2101
(212) 415-8700 Telephone
(212) 415-8701 Facsimile